Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

MYNZ

Mainz Biomed N.V.

Apr 18 • 04:00PM ET

0.9040

Dollar change -0.0272
Percentage change -2.92	%

Healthcare • Diagnostics & Research • Germany • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.64	Insider Own	21.68%	Shs Outstand	21.17M	Perf Week	-10.05%
Market Cap	15.14M	Forward P/E	-	EPS next Y	-0.74	Insider Trans	0.00%	Shs Float	13.12M	Perf Month	-12.23%
Income	-26.30M	PEG	-	EPS next Q	-0.23	Inst Own	1.39%	Short Float	2.34%	Perf Quarter	-15.51%
Sales	0.90M	P/S	16.82	EPS this Y	45.99%	Inst Trans	-2.24%	Short Ratio	3.65	Perf Half Y	-60.87%
Book/sh	0.15	P/B	5.89	EPS next Y	15.43%	ROA	-	Short Interest	0.31M	Perf Year	-83.20%
Cash/sh	0.42	P/C	2.14	EPS next 5Y	-	ROE	-	52W Range	0.85 - 6.00	Perf YTD	-22.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-595.61%	52W High	-84.93%	Beta	0.25
Dividend TTM	-	Quick Ratio	0.91	Sales past 5Y	25.92%	Gross Margin	-72.83%	52W Low	6.35%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	0.97	EPS Y/Y TTM	11.95%	Oper. Margin	-2975.47%	RSI (14)	38.36	Volatility	6.36% 7.47%
Employees	-	Debt/Eq	1.96	Sales Y/Y TTM	-	Profit Margin	-2936.50%	Recom	2.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	0.36	EPS Q/Q	-1124.50%	Payout	-	Rel Volume	0.62	Prev Close	0.93
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Apr 09 BMO	Avg Volume	84.19K	Price	0.90
SMA20	-12.17%	SMA50	-9.75%	SMA200	-57.15%	Trades		Volume	52,039	Change	-2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-21-22	Initiated	H.C. Wainwright	Buy	$25

Apr-10-24 12:47PM	The Pharmaceutical Industry Finds Itself At A Historical Crossroads (Benzinga) +6.06%
Apr-09-24 09:53PM	MYNZ Stock Earnings: Mainz Biomed Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.33%
08:01AM	Mainz Biomed Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-19-24 08:01AM	Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment (GlobeNewswire)
Mar-18-24 08:01AM	Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options (GlobeNewswire)
08:01AM	Loading…
Mar-12-24 08:01AM	Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations (GlobeNewswire)
Mar-08-24 12:00PM	What Makes Mainz Biomed NV (MYNZ) a New Buy Stock (Zacks)
Mar-05-24 08:01AM	Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic (GlobeNewswire)
Feb-28-24 12:54PM	Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening (Benzinga)
Feb-27-24 08:01AM	Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community (GlobeNewswire) -5.70%
Feb-22-24 02:21PM	Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment (Benzinga)
08:01AM	Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® (GlobeNewswire)
Feb-21-24 08:01AM	Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy (GlobeNewswire)
Feb-07-24 12:13PM	2024 Promises To Bring Pharmaceutical Breakthroughs On The Oncology Front (Benzinga)
Feb-06-24 08:01AM	Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany (GlobeNewswire)
04:17PM	Loading…
Feb-01-24 04:17PM	Pfizer Surprises With Profit But Revolutionizing Cancer Treatment Is Its Best Chance Of Getting Back In The Saddle (Benzinga)
Jan-11-24 08:01AM	Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gda sk Gastroenterology Symposium (GlobeNewswire)
Jan-09-24 03:40PM	2024 Marks a New Era Of Pharmaceutical Innovation (Benzinga)
08:01AM	Mainz Biomed Provides Year-End Corporate Review 2023 (GlobeNewswire)
Dec-29-23 02:48PM	2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer (Benzinga)
Dec-19-23 08:01AM	Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees (GlobeNewswire)
Dec-12-23 08:01AM	Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland (GlobeNewswire)
Dec-05-23 02:06PM	While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer (Benzinga) -24.53%
09:01AM	Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers (GlobeNewswire)
Nov-29-23 08:01AM	Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast (GlobeNewswire)
Nov-20-23 08:01AM	Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-16-23 08:01AM	Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-15-23 09:01AM	Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering (GlobeNewswire)
Nov-13-23 09:00AM	Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering (GlobeNewswire) -46.43%
Nov-09-23 08:01AM	Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test (GlobeNewswire) -17.14%
08:01AM	Loading…
Nov-07-23 08:01AM	Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA (GlobeNewswire) +13.45%
Nov-01-23 08:40AM	Why Is Mainz Biomed (MYNZ) Stock Moving Today? (InvestorPlace)
Oct-31-23 08:01AM	Mainz Biomed Reports Success from Employee Colorectal Cancer Screening Campaign in Partnership with Z ller-Kipper (GlobeNewswire)
Oct-26-23 08:01AM	Mainz Biomed Appoints Tarrin Khairi-Taraki as VP of Commercial Operations (GlobeNewswire)
Oct-18-23 08:01AM	Mainz Biomed Presents Groundbreaking Results of ColoFuture Study (GlobeNewswire)
Oct-17-23 03:16PM	Johnson & Johnson Was Saved By Its Focus On MedTech And Innovative Medicine (Benzinga)
Oct-11-23 08:01AM	Mainz Biomed to Showcase ColoAlert® at UEG Week 2023 in Copenhagen, Denmark (GlobeNewswire)
Oct-10-23 03:53PM	Big Pharma Could Transform Into BioTech Pharma (Benzinga) -9.77%
Oct-05-23 08:01AM	Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit (GlobeNewswire)
Oct-04-23 02:10PM	Mainz Biomed Continues To Transform Early Cancer Detection Across The Globe (Benzinga)
08:01AM	Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania (GlobeNewswire)
Sep-27-23 01:43PM	Mainz Biomed To Present The Power Of mRNA That Promises To Revolutionize Medicine (Benzinga)
08:01AM	Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology (GlobeNewswire)
Sep-22-23 02:51PM	AI To Revolutionize Clinical Trials And Diagnostics (Benzinga)
Sep-20-23 03:01AM	Mainz Biomed to Present at the Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire)
Sep-13-23 02:31PM	Mainz Biomed Paves The Way For Early Colorectal Cancer Diagnosis And Even Prevention (Benzinga) +15.85%
03:01AM	Mainz Biomeds ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81% (GlobeNewswire)
Sep-05-23 02:06PM	Cancer Remains Pharma's Biggest Challenge And Mainz Biomed Has The Tool To Help Win The Battle (Benzinga) +5.21%
03:01AM	Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market (GlobeNewswire)
Aug-29-23 03:01AM	Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +5.54%
Aug-22-23 03:01AM	Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland (GlobeNewswire)
Aug-15-23 03:01AM	Mainz Biomed Announces Financial Half Year Results 2023 and Provides Corporate Update (GlobeNewswire)
Aug-01-23 03:01AM	Mainz Biomed Announces Live Launch of ColoAlert® with Marylebone Laboratory in the United Kingdom (GlobeNewswire)
Jul-18-23 03:01AM	Mainz Biomed Announces Collaboration with Fugene Genetics in Israel (GlobeNewswire)
Jun-29-23 03:01AM	Mainz Biomed Secures up to $50M in New Funding (GlobeNewswire)
Jun-28-23 03:01AM	Mainz Biomed to Attend ESMO World Congress on Gastrointestinal Cancer 2023 in Barcelona, Spain (GlobeNewswire) +8.56%
Jun-20-23 03:01AM	Mainz Biomed Expands into Romania Through Partnership with Bioclinica (GlobeNewswire) -6.08%
May-31-23 03:01AM	Mainz Biomed Expands Commercial Footprint into Poland (GlobeNewswire) +6.40%
May-24-23 03:01AM	Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper (GlobeNewswire) +8.25%
May-21-23 08:08AM	Mainz Biomed First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-16-23 03:01AM	Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-23 03:01AM	Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert (GlobeNewswire) +11.66%
May-03-23 03:01AM	Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners (GlobeNewswire) +37.09%
May-01-23 03:01AM	Mainz Biomed to Participate in Digestive Disease Week 2023 (GlobeNewswire)
Apr-27-23 03:01AM	Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany (GlobeNewswire) +15.61%
Apr-26-23 03:01AM	Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal (GlobeNewswire)
Apr-10-23 03:01AM	Mainz Biomed Provides Full Year 2022 Financial Results (GlobeNewswire) -5.86%
Apr-04-23 03:01AM	Mainz Biomed Expands Corporate Health Program for ColoAlert with the Addition of Three New Companies in Germany (GlobeNewswire)
Mar-29-23 03:01AM	Mainz Biomed Reports Positive Results from Feasibility Study Evaluating its Portfolio of Novel mRNA Biomarkers for Early Detection of Advanced Colorectal Adenomas (GlobeNewswire)
Mar-21-23 03:01AM	Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23 (GlobeNewswire) +6.06%
Mar-20-23 02:00PM	Sidoti's Small-Cap Virtual March Conference (ACCESSWIRE) -7.42%
Mar-15-23 03:01AM	Mainz Biomed Announces Partnership with Labor Staber to Expand ColoAlert Commercialization in Germany (GlobeNewswire)
Mar-08-23 03:01AM	Mainz Biomed Launches Number of Educational Events in Germany to Raise Awareness for CRC Screening and Early Detection (GlobeNewswire)
Mar-01-23 03:01AM	Mainz Biomed Recognizes Colorectal Cancer Awareness Month Throughout Blue March 2023 (GlobeNewswire)
Feb-28-23 08:01AM	Mainz Biomed to Appear on ClearThink IRs Virtual Live Event on Wednesday, March 1, 2023 at 12 Noon ET (GlobeNewswire)
Feb-21-23 03:01AM	Mainz Biomed Acquires Entire Intellectual Property Portfolio for its Colorectal Cancer Diagnostic Test Program (GlobeNewswire)
Feb-15-23 03:01AM	Mainz Biomed Expands European Commercial Footprint and Enters Markets in Spain and UK (GlobeNewswire)
Jan-18-23 03:01AM	Mainz Biomed Launches Corporate Health Program in Germany for ColoAlert (GlobeNewswire)
Jan-03-23 03:01AM	Mainz Biomed Provides Year-End 2022 Corporate Review (GlobeNewswire) -7.04%
Dec-20-22 03:01AM	Mainz Biomed Enrolls First Patient in eAArly DETECT Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert (GlobeNewswire) +5.68%
Dec-06-22 03:01AM	Mainz Biomed Announces IRB Approval and Initiation of US Pivotal FDA Clinical Study (GlobeNewswire) +10.00%
Nov-29-22 08:00AM	Mainz Biomed Appoints Amy Levin as Vice President of Regulatory Affairs to Oversee Global Regulatory Strategies (GlobeNewswire)
Nov-22-22 08:00AM	Mainz Biomed to Participate in Deutsche Eigenkapitalforum and Cantor Fitzgeralds Medical & Aesthetic Dermatology, Ophthalmology & MedTech Conference (GlobeNewswire)
Nov-15-22 08:00AM	Mainz Biomed Announces U.S. Extension of ColoFuture Study to Evaluate Integration of Novel mRNA Biomarkers into ColoAlert (GlobeNewswire)
Nov-02-22 08:00AM	Mainz Biomed Provides Third Quarter 2022 Update (GlobeNewswire)
Sep-28-22 07:00AM	Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts (GlobeNewswire)
Sep-20-22 03:01AM	Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board (GlobeNewswire)
Sep-07-22 03:01AM	Mainz Biomed Reports First Half 2022 Financial Results (GlobeNewswire)
Sep-01-22 03:01AM	Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference (GlobeNewswire)
Aug-23-22 03:01AM	Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board (GlobeNewswire)
Aug-16-22 03:01AM	Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates (GlobeNewswire) +15.15%
Aug-03-22 07:44AM	Here's What Mainz Biomed B.V.'s (NASDAQ:MYNZ) Shareholder Ownership Structure Looks Like (Simply Wall St.)
03:01AM	Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development (GlobeNewswire)
Jul-19-22 03:01AM	Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board (GlobeNewswire)
Jul-12-22 03:01AM	Mainz Biomed Today to Provide Corporate Update for First Half of 2022 (GlobeNewswire)
Jul-05-22 03:01AM	Mainz Biomed Provides Corporate Update for First Half of 2022 (GlobeNewswire)
Jun-28-22 03:01AM	Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert (GlobeNewswire)
Jun-14-22 03:01AM	Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission (GlobeNewswire)
Jun-01-22 03:01AM	Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance (GlobeNewswire)
May-19-22 03:01AM	Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE) (GlobeNewswire)

Mainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MYNZ

Mainz Biomed N.V.

Upgrade your FINVIZ experience